Cross-sectional studies have indicated potential for positron emission tomography (PET) in imaging tau pathology in Alzheimer’s disease (AD); however, its prognostic utility remains unproven. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.